Step Pharma SAS
🇫🇷France
- Country
- 🇫🇷France
- Ownership
- Holding
- Established
- 2014-06-01
- Employees
- 1
- Market Cap
- -
- Website
- http://www.step-ph.com
A Phase 1 Study to Assess STP938 as a Monotherapy in Adults With High Risk Essential Thrombocythaemia
- First Posted Date
- 2025-01-22
- Last Posted Date
- 2025-04-15
- Lead Sponsor
- Step Pharma, SAS
- Target Recruit Count
- 20
- Registration Number
- NCT06786234
- Locations
- 🇬🇧
Cancer and Haematology Centre, Churchill Hospital, Oxford, United Kingdom
Study of STP938 in Advanced Solid Tumours
- First Posted Date
- 2024-03-07
- Last Posted Date
- 2025-04-15
- Lead Sponsor
- Step Pharma, SAS
- Target Recruit Count
- 70
- Registration Number
- NCT06297525
- Locations
- 🇫🇷
Institut Gustave Roussy, Villejuif, Paris, France
🇬🇧University College London, London, United Kingdom
🇺🇸Comprehensive Hematology Oncology, LLC, Saint Petersburg, Florida, United States
A Phase 1/2 Study of STP938 for Adult Subjects With Relapsed/Refractory B-Cell and T-Cell Lymphomas
- First Posted Date
- 2022-07-18
- Last Posted Date
- 2025-04-15
- Lead Sponsor
- Step Pharma, SAS
- Target Recruit Count
- 180
- Registration Number
- NCT05463263
- Locations
- 🇺🇸
Memorial Sloan Kettering, New York, New York, United States
🇫🇷Hôpital Saint-Louis, Paris, France
🇺🇸Colorado Blood Cancer Institute, Denver, Colorado, United States
© Copyright 2025. All Rights Reserved by MedPath